Access, Tolerability, and Trial Limitations: Practical Decision-Making in CRPC
Автор: GU Oncology Now
Загружено: 2025-09-24
Просмотров: 29
A regional roundtable discussion, moderated by Shilpa Gupta, MD, Cleveland Clinic, examined current and emerging strategies in mHSPC and CRPC, including biomarkers and imaging in treatment selection, evolving use of doublet and triplet therapy, ARPI choices and toxicity considerations, and more. Dr. Gupta was joined by other practitioners at Cleveland Clinic, including Christopher Wee, MD; Abdo Haddad, MD; Adriana Alvarez, MD; Moshe Ornstein, MD; and Brian Haines, MD.
In the sixth segment, they discuss how real-world data informs clinical practice without necessarily changing it, emphasizing that patient-specific factors like age, comorbidities, and treatment goals are key drivers in decision-making. They also explore the use of bone-directed therapies, including radium-223 and lutetium, weighing potential benefits against toxicity and access limitations.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
